Patent: 7,902,202
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 7,902,202
Title: | Compounds and pharmaceutical compositions for the treatment of viral infections |
Abstract: | Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. |
Inventor(s): | Sommadossi; Jean-Pierre (Cambridge, MA), Gosselin; Gilles (Montpellier, FR), Pierra; Claire (Montarnaud, FR), Perigaud; Christian (Grabels, FR), Peyrottes; Suzanne (Grabels, FR) |
Assignee: | Idenix Pharmaceuticals, Inc. (Cambridge, MA) L\'Universite Montpellier II (Montpellier, FR) |
Application Number: | 12/150,327 |
Patent Claims: | see list of patent claims |
Details for Patent 7,902,202
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | See Plans and Pricing | 2026-12-28 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | See Plans and Pricing | 2026-12-28 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 02/27/2012 | See Plans and Pricing | 2026-12-28 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 03/07/2002 | See Plans and Pricing | 2026-12-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |